Sexually Transmitted Infections

Urologic Clinics of North America

Volumn 42, Issue 4, 2015, Pages 507-518

  Smith, Lindsay ^a   Angarone, Michael P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chlamydia; Gonorrhea; HPV; HSV; STI; Syphilis

Indexed keywords

ACICLOVIR; AZITHROMYCIN; BENZATHINE PENICILLIN; CEFIXIME; CEFTRIAXONE; DICHLOROACETIC ACID; DOXYCYCLINE; FAMCICLOVIR; IMIQUIMOD; METRONIDAZOLE; PENICILLIN G; PODOPHYLLIN; PODOPHYLLOTOXIN; PROBENECID; PROCAINE PENICILLIN; TINIDAZOLE; TRICHLOROACETIC ACID; VALACICLOVIR; WART VIRUS VACCINE; ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT;

BEHAVIOR MODIFICATION; CHLAMYDIASIS; CLINICAL FEATURE; CONDYLOMA; COUNSELING; CRYOTHERAPY; ELECTROSURGERY; EPIDIDYMITIS; FLUORESCENT ANTIBODY TECHNIQUE; GENITAL HERPES; GENITAL ULCER; GONORRHEA; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; INCIDENCE; LASER SURGERY; MEN WHO HAVE SEX WITH MEN; MICROSCOPY; MORBIDITY; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PAPILLOMAVIRUS INFECTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SCREENING TEST; SECONDARY SYPHILIS; SENSITIVITY ANALYSIS; SERODIAGNOSIS; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; SYPHILIS; TRICHOMONIASIS; UNITED STATES; URETHRITIS; UTERINE CERVICITIS; VAGINA DISCHARGE; VAGINITIS; WART VIRUS; CHLAMYDIA INFECTIONS; COMPLICATION; CONDYLOMATA ACUMINATA; CONTACT EXAMINATION; FEMALE; GRANULOMA INGUINALE; HERPES GENITALIS; LYMPHOGRANULOMA VENEREUM; MALE; MICROBIOLOGY; TRICHOMONAS VAGINITIS; ULCER; ULCUS MOLLE; VIROLOGY;

ANTI-BACTERIAL AGENTS; ANTIPROTOZOAL AGENTS; CHANCROID; CHLAMYDIA INFECTIONS; CONDYLOMATA ACUMINATA; CONTACT TRACING; EPIDIDYMITIS; FEMALE; GONORRHEA; GRANULOMA INGUINALE; HERPES GENITALIS; HUMANS; LYMPHOGRANULOMA VENEREUM; MALE; PAPILLOMAVIRUS VACCINES; SYPHILIS; TRICHOMONAS VAGINITIS; ULCER; URETHRITIS; UTERINE CERVICITIS; VAGINAL DISCHARGE;

EID: 84945483007     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2015.06.004     Document Type: Review

References (60)

1. Centers for Disease Control and Prevention Sexually transmitted infections surveillance 2013 2014, U.S. Department of Health and Human Services, Atlanta (GA).
2. Aral S.O., Holmes K.K., Padian N.S., et al. Overview: individual and population approaches to the epidemiology and prevention of sexually transmitted diseases and human immunodeficiency virus infection. J Infect Dis 1996, 174(Suppl 2):S127-S133.
3. Workowski K.A., Berman S., Centers for Disease Control Prevention Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010, 59(RR-12):1-110.
4. Jena A.B., Goldman D.P., Kamdar A., et al. Sexually transmitted diseases among users of erectile dysfunction drugs: analysis of claims data. Ann Intern Med 2010, 153(1):1-7.
5. Leder K., Torresi J., Libman M.D., et al. GeoSentinel surveillance of illness in returned travelers, 2007-2011. Ann Intern Med 2013, 158(6):456-468.
6. U.S.Preventive Services Task Force Behavioral counseling to prevent sexually transmitted infections: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149(7):491-496. W95.
7. Lin J.S., Whitlock E., O'Connor E., et al. Behavioral counseling to prevent sexually transmitted infections: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008, 149(7):497-508. W96-9.
8. Perez G., Skurnick J.H., Denny T.N., et al. Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study. Int J Infect Dis 1998, 3(1):5-11.
9. Zetola N.M., Engelman J., Jensen T.P., et al. Syphilis in the United States: an update for clinicians with an emphasis on HIV coinfection. Mayo Clin Proc 2007, 82(9):1091-1102.
10. Marra C.M., Maxwell C.L., Smith S.L., et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis 2004, 189(3):369-376.
11. Ghanem K.G., Erbelding E.J., Cheng W.W., et al. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis 2006, 42(6):e45-e49.
12. Xu F., Sternberg M.R., Kottiri B.J., et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296(8):964-973.
13. Corey L., Adams H.G., Brown Z.A., et al. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983, 98(6):958-972.
14. Klausner J.D., Kohn R., Kent C. Etiology of clinical proctitis among men who have sex with men. Clin Infect Dis 2004, 38(2):300-302.
15. Scoular A. Using the evidence base on genital herpes: optimising the use of diagnostic tests and information provision. Sex Transm Infect 2002, 78(3):160-165.
16. Krantz I., Lowhagen G.B., Ahlberg B.M., et al. Ethics of screening for asymptomatic herpes virus type 2 infection. BMJ 2004, 329(7466):618-621.
17. Lewis D.A. Chancroid: clinical manifestations, diagnosis, and management. Sex Transm Infect 2003, 79(1):68-71.
18. Lewis D.A., Ison C.A. Chancroid. Sex Transm Infect 2006, 82(Suppl 4):iv19-iv20.
19. Pilatz A., Hossain H., Kaiser R., et al. Acute epididymitis revisited: impact of molecular diagnostics on etiology and contemporary guideline recommendations. Eur Urol 2014, [Epub ahead of print].
20. Tracy C.R., Steers W.D., Costabile R. Diagnosis and management of epididymitis. Urol Clin North Am 2008, 35(1):101-108. vii.
21. U.S.Preventive Services Task Force Screening for chlamydial infection: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007, 147(2):128-134.
22. Meyers D., Wolff T., Gregory K., et al. USPSTF recommendations for STI screening. Am Fam Physician 2008, 77(6):819-824.
23. U.S.Preventive Services Task Force Screening for gonorrhea: recommendation statement. Ann Fam Med 2005, 3(3):263-267.
24. Centers for Disease Control and Prevention Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012, 61(31):590-594.
25. Kirkcaldy R.D., Bolan G.A., Wasserheit J.N. Cephalosporin-resistant gonorrhea in North America. JAMA 2013, 309(2):185-187.
26. Bradshaw C.S., Tabrizi S.N., Read T.R., et al. Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis 2006, 193(3):336-345.
27. Bradshaw C.S., Chen M.Y., Fairley C.K. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS One 2008, 3(11):e3618.
28. Dunne E.F., Unger E.R., Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297(8):813-819.
29. Myers E.R., McCrory D.C., Nanda K., et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000, 151(12):1158-1171.
30. Ho G.Y., Bierman R., Beardsley L., et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338(7):423-428.
31. Garland S.M., Steben M., Sings H.L., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009, 199(6):805-814.
32. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997, 102(5A):3-8.
33. Nelson E.L., Stockdale C.K. Vulvar and vaginal HPV disease. Obstet Gynecol Clin North Am 2013, 40(2):359-376.
34. Datta S.D., Koutsky L.A., Ratelle S., et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med 2008, 148(7):493-500.
35. Jones R.W., Rowan D.M., Stewart A.W. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 2005, 106(6):1319-1326.
36. Rodriguez A.C., Schiffman M., Herrero R., et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008, 100(7):513-517.
37. Perry C.M., Lamb H.M. Topical imiquimod: a review of its use in genital warts. Drugs 1999, 58(2):375-390.
38. Bonnez W., Elswick R.K., Bailey-Farchione A., et al. Efficacy and safety of 0.5% podofilox solution in the treatment and suppression of anogenital warts. Am J Med 1994, 96(5):420-425.
39. Tyring S.K., Arany I., Stanley M.A., et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998, 178(2):551-555.
40. Garland S.M., Waddell R., Mindel A., et al. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Int J STD AIDS 2006, 17(7):448-452.
41. Gotovtseva E.P., Kapadia A.S., Smolensky M.H., et al. Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis. Sex Transm Dis 2008, 35(4):346-351.
42. Edwards L., Ferenczy A., Eron L., et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 1998, 134(1):25-30.
43. Stockfleth E., Beti H., Orasan R., et al. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 2008, 158(6):1329-1338.
44. Tatti S., Swinehart J.M., Thielert C., et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008, 111(6):1371-1379.
45. Lacey C.J., Woodhall S.C., Wikstrom A., et al. 2012 European guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol 2013, 27(3):e263-e270.
46. American College of Obstetricians and Gynecologists ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol 2005, 105(4):905-918.
47. Zhou J., Sun X.Y., Stenzel D.J., et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991, 185(1):251-257.
48. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943.
49. FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):1915-1927.
50. Paavonen J., Naud P., Salmeron J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
51. Giuliano A.R., Palefsky J.M., Goldstone S., et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011, 364(5):401-411.
52. Palefsky J.M., Giuliano A.R., Goldstone S., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365(17):1576-1585.
53. Joura E.A., Giuliano A.R., Iversen O.E., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015, 372(8):711-723.
54. Petrosky E., Bocchini J.A., Hariri S., et al. Use of 9-Valent Human Papillomavirus (HPV) Vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2015, 64(11):300-304.
55. LeFevre M.L., U.S.Preventive Services Task Force Behavioral counseling interventions to prevent sexually transmitted infections: U.S. PreventiveServices Task Force recommendation statement. Ann Intern Med 2014, 161(12):894-901.
56. O'Connor E.A., Lin J.S., Burda B.U., et al. Behavioral sexual risk-reduction counseling in primary care to prevent sexually transmitted infections: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2014, 161(12):874-883.
57. Haukoos J.S., Thrun M.W. Eliminating prevention counseling to improve HIV screening. JAMA 2013, 310(16):1679-1680.
58. Golden M.R., Whittington W.L., Handsfield H.H., et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005, 352(7):676-685.
59. Kissinger P., Mohammed H., Richardson-Alston G., et al. Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. Clin Infect Dis 2005, 41(5):623-629.
60. Hogben M. Partner notification for sexually transmitted diseases. Clin Infect Dis 2007, 44(Suppl 3):S160-S174.